Meeting
2023 ASCO Annual Meeting
First-in-human trial of tocilizumab in combination with a standard induction chemotherapy in newly diagnosed acute myeloid leukemia patients: The phase 1 TOCILAM study.
Authors
Pierre Peterlin
CHU de Nantes, Service d'hématologie Clinique, Nantes, France
Pierre Peterlin , Alice Garnier , Amandine Le Bourgeois , Thierry Guillaume , Maxime Jullien , Lucie Planche , Joelle Gaschet , Patrice Chevallier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04547062
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7028)
DOI
10.1200/JCO.2023.41.16_suppl.7028
Abstract #
7028
Poster Bd #
158
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML.
First Author: Prajwal Boddu
First Author: Kimberly Stephanie Meza
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca